Press Release

Global health technology and human data sciences company, IQVIA, welcomes Baroness Fairhead to UK HQ after £46m Sector Deal announcements.

The UK’s Minister for Trade and Export Promotion, Baroness Rona Fairhead, today (Thursday 6th December) visited IQVIA’s UK London Office, to highlight the transformative impact of the Second Life Sciences Sector Deal announced by the Government on Wednesday 5th December. IQVIA is a human data sciences company formed through the 2016 merger of IMS Health and Quintiles, providing solutions that harness advances in clinical research, healthcare information, technology, analytics and human ingenuity to improve patient outcomes.

As part of the Second Life Sciences Sector Deal refresh, IQVIA, facilitated by the National Institute for Health Research (NIHR), has committed to opening a fourth UK Prime Site to focus on the delivery of life-changing clinical research across the North of England which includes investing up to £24m over five years with plans to employ over 50 additional highly-skilled staff to drive additional trials across the UK. The Northern Prime Site will include NHS research-ready hospitals across the Greater Manchester, Leeds and Sheffield region. The new site will embrace a data-enabled approach to the design and delivery of hundreds of additional clinical trials and real-world evidence studies which will benefit thousands of NHS patients. IQVIA currently conducts 25% of all commercial clinical trials in the NHS.

In addition, IQVIA will invest £20m over five years in a new partnership with Genomics England to develop services to allow authorised researchers to run studies enabling faster and more efficient drug research, and to develop more robust evidence to support treatment value and greater access to personalised medicines for NHS patients.

The announcement is a key development in IQVIA’s mission to drive healthcare forward through world-leading clinical trials and real-world evidence providing domain expertise, unparalleled data, transformative technology and advanced analytics including artificial intelligence. 

Baroness Fairhead, UK Government Minister for Trade and Export Promotion, met IQVIA researchers, senior management and scientific staff as well as clinicians from clinical trials sites and research patients at the IQVIA London office. Speaking after her visit, she said: “IQVIA are a great example of a global company who are making the most of the fantastic environment for life sciences companies in the UK.

“Our higher education system and the access to world leading research and development facilities in the UK mean that companies have the ability to make innovative advancements that can change the lives of millions of people.

“I would encourage all businesses to make the most of the measures in the government’s Life Sciences Sector Deal, as well as the offer set out in our Export Strategy as they look to expand their overseas operations.” 

Tim Sheppard, Senior Vice President (SVP) and General Manager, Northern Europe IQVIA, said: “This is a landmark investment for IQVIA, but crucially one which will deliver help for patients across the UK, and trade benefits for the UK across the world.

“IQVIA believes in the UK’s potential to be a unique bioscience centre of excellence in life sciences, and this investment further supports the UK Government and the industry’s aim to ensure this potential is realised. That centre of excellence status provides the opportunity to cement and extend our industry’s global leadership, developing a life sciences sector that can be truly world-leading. Vitally, this is also a platform from which we can build even greater sector momentum behind the overall UK Industrial Strategy.”

IQVIA has committed to opening a fourth UK Prime Site to focus on the delivery of life-changing clinical research across the North of England which includes investing up to £24m over five years with plans to employ over 50 additional highly-skilled staff to drive additional trials across the UK. The Northern Prime Site will include NHS research-ready hospitals across the Greater Manchester, Leeds and Sheffield region. The new site will embrace a data-enabled approach to the design and delivery of hundreds of additional clinical trials and real-world evidence studies which will benefit thousands of NHS patients. IQVIA currently conducts 25% of all commercial clinical trials in the NHS.

In addition, IQVIA will invest £20m over five years in a new partnership with Genomics England to develop services to allow authorised researchers to run studies enabling faster and more efficient drug research, and to develop more robust evidence to support treatment value and greater access to personalised medicines for NHS patients. 

The Second Life Sciences Sector Deal is the extension of a previous set of deals announced alongside the UK’s Industrial Strategy in November 2017. Each deal represents a new strategic and long-term partnership with Government, backed by private sector co-investment and will drive investment in the UK’s world-leading research infrastructure and boost productivity in the sector.

About IQVIA
IQVIA (NYSE: IQV) is a leading global provider of information, innovative technology solutions and contract research services focused on helping healthcare clients find better solutions for patients. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialisation, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With more than 55,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analysing the information that helps their customers drive human health outcomes forward. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviours and scientific advances, to advance their path toward cures. To learn more, visit www.IQVIA.com